The endocrine system regulates metabolism through a network of hormones, receptors, and feedback loops. When these pathways are activated or modulated, the body adjusts how it stores fat, releases energy, and distributes adipose tissue. Three peptides have become the focus of significant research interest for the roles they appear to play in metabolic signaling.
Retatrutide
What it is: A triple-receptor agonist that activates multiple metabolic receptor pathways simultaneously. In a Phase 3 clinical trial, Retatrutide simultaneously targets three receptor pathways (incretin, GIP, and glucagon), making it one of the most closely watched metabolic peptides in current research. Source
How It Works
What Researchers Study It For
Common Research Protocols
Retatrutide is currently under clinical investigation as a subcutaneous injection. Research protocols are defined within the context of ongoing clinical trials. Source
Community Interest Areas
The research community has shown intense interest in Retatrutide due to its triple-agonist mechanism, which distinguishes it from dual-agonist compounds. Its ability to engage the glucagon receptor in addition to incretin pathways has generated particular attention in metabolic research circles focused on energy expenditure.
Tesamorelin
What it is: A synthetic analog of GHRH (growth hormone-releasing hormone) consisting of 44 amino acids. In a 404-patient clinical trial, Tesamorelin demonstrated statistically significant reductions in visceral adipose tissue. Source
How It Works
What Researchers Study It For
Common Research Protocols
Tesamorelin is reconstituted from lyophilized powder and administered via subcutaneous injection. Source
Community Interest Areas
Tesamorelin draws significant research interest for its specificity toward visceral adipose tissue rather than subcutaneous fat. The research community has explored it extensively in body composition studies, particularly in contexts where visceral fat accumulation is a primary variable. Its mechanism of stimulating endogenous GH release, rather than introducing exogenous GH, is a key point of differentiation.
AOD 9604
What it is: A modified fragment of human growth hormone, specifically amino acids 177–191 with a tyrosine addition. It was designed to isolate the fat-metabolizing activity of growth hormone without its growth-promoting or diabetogenic effects. Source
How It Works
What Researchers Study It For
Common Research Protocols
AOD 9604 is typically reconstituted from lyophilized powder with bacteriostatic water and administered via subcutaneous injection. In preclinical studies, it has been investigated in both oral and injectable formats. Research dosing varies by study design, with many protocols exploring fasted-state administration to maximize lipolytic activity. Source
Community Interest Areas
AOD 9604 draws research interest for its targeted approach to fat metabolism. Because it is a fragment of growth hormone rather than the full molecule, researchers study it as a way to isolate lipolytic effects without influencing blood sugar or stimulating tissue growth. It is frequently explored in combination with other metabolic peptides in multi-pathway protocols.
How They Compare
Key Takeaways
- Retatrutide is a triple-receptor agonist targeting multi-receptor metabolic pathways simultaneously, the first compound studied across all three pathways simultaneously
- Tesamorelin stimulates endogenous growth hormone release via the GHRH receptor, with clinical research demonstrating selective reduction of visceral adipose tissue in a 404-patient trial
- AOD 9604 isolates the lipolytic fragment of growth hormone to promote fat breakdown without growth-related or diabetogenic effects
- Each peptide approaches metabolic signaling through a different mechanism, reflecting the multiple pathways the body uses to regulate energy storage and expenditure
- The statements made on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). All products sold by 33 Degrees of Healing are provided strictly for research, laboratory, and investigational purposes only.
Frequently Asked Questions
What do Retatrutide, Tesamorelin, and AOD 9604 have in common?
All three are studied in the context of endocrine and metabolic signaling, though each engages a different mechanism. Retatrutide is a triple-receptor agonist studied across the incretin, GIP, and glucagon pathways, Tesamorelin is a GHRH analog studied for stimulating endogenous growth hormone release, and AOD 9604 is a growth hormone fragment studied for its lipolytic activity. Each approaches metabolic signaling through a different pathway.
How does Retatrutide differ from dual-agonist compounds?
Retatrutide is studied as a triple-receptor agonist that engages three receptor pathways (incretin, GIP, and glucagon) simultaneously, whereas dual-agonist compounds engage two. Its engagement of the glucagon receptor in addition to the incretin pathways is what distinguishes it in metabolic research and has generated particular attention in research circles focused on energy expenditure.
What is the difference between Tesamorelin and AOD 9604?
Tesamorelin is a synthetic analog of GHRH studied for binding GHRH receptors on the pituitary to stimulate the release of endogenous growth hormone, which is examined in relation to visceral adipose tissue. AOD 9604 is a modified fragment of human growth hormone studied for isolating the fat-metabolizing activity of growth hormone without its growth-promoting or diabetogenic effects. They are studied at different points in the growth hormone pathway.
How are these metabolic compounds administered in research protocols?
In published research, these compounds are typically reconstituted from lyophilized powder and administered via subcutaneous injection. Retatrutide is under clinical investigation as a subcutaneous injection, Tesamorelin is reconstituted from lyophilized powder for subcutaneous injection, and AOD 9604 is reconstituted with bacteriostatic water and has been investigated in both oral and injectable formats.
Are Retatrutide, Tesamorelin, and AOD 9604 approved for human use?
No. Retatrutide, Tesamorelin, and AOD 9604 are research compounds that have not been approved by the FDA for human use. They are studied in laboratory, preclinical, and clinical research settings and are sold for research, laboratory, and investigational purposes only.
Related Research Compounds
Read the Full Scientific Review →
Sources
- Eli Lilly. Retatrutide clinical trial program. ClinicalTrials.gov. ClinicalTrials.gov
- Falutz J, et al. Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients. JAMA. 2010. PubMed
- Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001. PubMed
- Coskun T, et al. Retatrutide, a triple incretin receptor agonist, for obesity. N Engl J Med. 2023. PMC
This article is for educational and research purposes only. It is not intended as medical advice. The compounds discussed are research chemicals not approved by the FDA for human use. Always consult qualified professionals and review current regulations before conducting any research.